

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066679 A1

(51) International Patent Classification⁷: **C07K 14/705**,
16/30, G01N 33/574, A61K 38/17, 39/395, A61P 35/00

(21) International Application Number: PCT/AU03/00135

(22) International Filing Date: 7 February 2003 (07.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PS 0364 7 February 2002 (07.02.2002) AU

(71) Applicant (for all designated States except US): **SOLBEC PHARMACEUTICALS LIMITED** [AU/AU]; Level 1, 10 Stirling Highway, Nedlands, Western Australia 6009 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIPSCOMBE, Richard, J** [AU/AU]; Level 21, 97 St Georges Terrace,

Perth, Western Australia 6000 (AU). **CARTER, Stephen, John** [AU/AU]; 8 Baybury Rise, Woodvale, Western Australia 6026 (AU). **RUANE, Michael** [AU/AU]; 167 Ardross Street, Applecross, Western Australia 6153 (AU).


(74) Agent: **WRAY & ASSOCIATES**; Level 4, The Quadrant, 1 William Street, Perth, Western Australia 6000 (AU).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: RHAMNOSE BINDING PROTEIN



(57) Abstract: An isolated RBP with at least one of the following characteristics: a) a molecular weight of approximately 65-70 kDa and more preferably 66-69kDa; b) a pI of greater than 10 or less than 3; c) a dissociation constant of approximately 1.5×10^{-6} when bound to the rhamnose moiety of solamargine; d) adapted to bind to a rhamnose affinity column prepared according to example 1 and under the conditions set out therein; e) adapted to be eluted from the column in example 1 with a 100mM rhamnose solution; f) insoluble in aqueous solution; and g) soluble in highly denaturing buffers containing greater than approximately 2% surfactant.

WO 03/066679 A1

WO 03/066679 A1



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

"Rhamnose Binding Protein"

Field of the Invention

The present invention relates to an isolated rhamnose binding protein (RBP) that is over expressed in cancer cells relative to non-cancer cells. The present
5 invention also relates to methods of diagnosing cancer by detecting RBP levels and to RBP agonists such as antibodies and methods of treating and diagnosing cancer using RBP agonists.

Background Art

BEC® is a mixture of the triglycosides: solasonine and solamargine that has anti-
10 cancer activity. Studies on the mode of action of BEC® indicate that the glycosides gain entry to cancer cells via a cell surface receptor and that the in vitro toxicity of BEC® to cancer cells is reduced by co-administration of rhamnose.

The presence of endogenous endocytic ligand receptors (EEL) has been an area of clinical research for over 2 decades. The first EEL to be identified was the
15 asialoglycoprotein receptor on mammalian hepatocytes with specificity for galactose (Ashwell & Hardford 1982). Since this time other hepatic receptors have been identified. For example, fucose (Lehrman *et al* 1986), GalNAc (Kolb-Bachofen *et al* 1984), as well as a number of cell receptors identified by Cramer and Gabius (1991). EEL's may be involved in cellular recognition, cell adhesion
20 or substrate binding.

To date no one has isolated and/or characterised the cell surface receptor that is central to BEC®'s mode of action. The present invention seeks to overcome or at least partially alleviate this problem.

Summary of the Invention

25 The present invention provides an isolated RBP with at least one of the following characteristics:

- (a) a molecular weight of approximately 65-70 kDa and more preferably 66-69kDa;
- (b) a pI of greater than 10 or less than 3;
- (c) a dissociation constant of approximately 1.5×10^{-6} when bound to the
5 rhamnose moiety of solamargine;
- (d) adapted to bind to a rhamnose affinity column prepared according to example 1 and under the conditions set out therein ;
- (e) adapted to be eluted from the column in example 1 with a 100mM rhamnose solution;
- 10 (f) insoluble in aqueous solution; and
- (g) soluble in highly denaturing buffers containing greater than approximately 2% surfactant.

The ability of the RBP to bind ligands such as rhamnose to a RBP bearing cell, such as a carcinoma, render it useful in various methods. For example, it has
15 been found that when the RBP binds a ligand, such as rhamnose, cell adhesion of the RBP bearing cells is inhibited. Thus, the present invention also provides a method of inhibiting cell adhesion between RBP bearing cells comprising the step of contacting the RBP bearing cells with an effective amount of a RBP ligand. The effective amount may be varied depending on the circumstances and may be
20 determined by those skilled in the art. However, when the RBP ligand is rhamnose the effective amount may be approximately 70 picograms/cell.

Upon binding of a ligand to a cell associated RBP of the present invention, depending on the ligand, the ligand may be internalised in the cell or remain on the cell surface. Whether or not a ligand is internalised after binding to a cell
25 associated RBP of the present invention depends on a variety of factors such as the molecular weight, charge, structure and/or biological activity of the ligand.

Thus, the present invention also provides a method of delivering an agent to a RBP bearing cell comprising contacting an agent-ligand complex with the RBP bearing cell.

The agent may be delivered to the cell surface or inside the cell by selecting an appropriate ligand-agent complex. For example, by selecting an agent-complex of a certain molecular weight or structure it is possible to control the delivery of the agent to the cell surface or the inside of the cell. In this regard, it has been found that if the agent is above a certain threshold weight then it cannot be efficiently internalised in by the RBP bearing cell and will remain at the cell surface.

The ability of RBP to bind ligands and either internalise or retain them on a cell surface, means the RBP may be utilised to locate and identify RBP bearing cells. Thus, the present invention also provides a method of detecting a RBP bearing cell comprising the steps of: (i) contacting a cell or tissue sample with an agent adapted to selectively bind to RBP and (ii) detecting the RBP bearing cells.

The agent may be varied and includes antibodies and other ligands or agonists that are adapted to bind to RBP. Furthermore, to ease detection of the RBP bearing cells the agent may be adapted to be visualised.

Thus, the RBP of the present invention may be used to identify agents that bind to the RBP and thus can be used in assays for the RBP, as diagnostics to identify RBP bearing cells or to target therapeutic agents to cancer cells via the RBP. The RBP may also form a component of a screening system for antagonists or agonists of agents that bind to the RBP.

These and additional uses for the reagents described herein will become apparent to those of ordinary skill in the art upon reading this specification.

Brief Description of the Figures

Figure 1: depicts a PAGE gel containing fractions 1-9 eluted from a biotinylated rhamnose-ITC affinity column using 100mM free rhamnose and lane 10 contains standard molecular weight markers;

- 5 Figure 2A: is a fluoro-image of proteins crosslinked to FRITC and analysed on a 4-20% polyacrylamide gel. Standards (tagged with assorted coloured dyes hence some visible by fluoro-imaging); Sample: 1) 5µM FRITC (Batch 1) + 100µM CDI; 2) 5µM FRITC + 500µM CDI; 3) 5µM FRITC + 10mM CDI; 4) 5µM FRITC (Batch 2) + 100µM CDI; 5) No FRITC + 100µM CDI; 6) No FRITC + 500µM CDI;
- 10 Figure 2B: is the total proteins from the gel depicted in Figure 2A stained with Coomassie brilliant blue;
- Figure 3: is a graph used to calculate the molecular mass of the proteins in Figure 2A;
- Figure 4: is an image of A2058 cells following incubation with 12µM fluorescein
- 15 rhamnose-ITC at 37°C for 15min in HEPES buffered saline containing 2mM Ca^{2+} and Mg^{2+} ;
- Figure 5: is a plot of the relationship between dose per cell at LD_{50} and the Day 1 cell density for each cell line;
- Figure 6: depicts the data in Figure 5 condensed and fitted to a single exponential
- 20 function;
- Figure 7: is a plot of the relationship between dose per cell at LD_{50} and the Day 1 cell density for two particular breast cancer lines;
- Figure 8: is a comparison of the plots in Figures 6 and 7;
- Figure 9: is table containing single point LD_{50} data from another 11 carcinomas;
- 25 Figure 10: is a graphical representation of the data presented in the table in Figure 9; and
- Figure 11: illustrates the protective effects of rhamnose when co-administered with BEC® via a graph of % cell (A2058, 600 cells) survival v's concentration of BEC®;
- 30 Figure 12: illustrates the protective effects of rhamnose when co-administered with BEC® via a graph of % cell (A2058, 5000 cells) survival v's concentration of BEC®;

Figure 13 illustrates a fluoro-image of A2058 proteins crosslinked to FRITC, solvent extracted and analysed on a 4-20% SDS polyacrylamide gel. From left, Lane 1: Standards 83, 42.3, 32.2, 18.8kD; Lane 2 blank; Lanes 3-8: replicate flasks of cells + approx 5µM FRITC + 100µM carbonyl di-imidazole; and

- 5 Figure 14 illustrates immunoprecipitation of FRITC –protein cross-linked complex analysed on a 4-20% SDS polyacrylamide gel.

Total protein stain - Lane 1: Standards 206, 124, 83, 42.3, 32.2, 18.8kD;

Both); Lane 2 Protein A pre-clear (-ve); Lane 3 α-FITC antibody precipitation

Detailed Description of the Invention

10 Rhamnose binding protein (RBP)

The present invention is based on the isolation and identification of a cellular receptor of the lectin group that is more abundant on neoplastic (cancer) cells than non-cancer cells. The receptor ("RBP") is adapted to bind and internalise rhamnose and thus represents a valuable diagnostic and therapeutic tool.

- 15 The present invention provides an isolated RBP comprising at least one of the following characteristics:

(a) a molecular weight of approximately 65-70 kDa and more preferably 66-69kDa;

(b) a pI of greater than 10 or less than 3;

- 20 (c) a dissociation constant of approximately 1.5×10^{-6} when bound to the rhamnose moiety of solamargine;

(d) adapted to bind to a rhamnose affinity column prepared according to example 1 and under the conditions set out therein ;

- 25 (e) adapted to be eluted from the column in example 1 with a 100mM rhamnose solution;

(f) insoluble in aqueous solution; and

(g) soluble in highly denaturing buffers containing greater than approximately 2% surfactant.

Throughout the specification, unless the context requires otherwise, the word
5 "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

The RBP and other polypeptides of the invention may be in a substantially isolated form. In this regard, it will be understood that they may be mixed with
10 carriers or diluents that will not interfere with their intended purpose and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which at least 90%, 95%, 98% or 99% of the protein in the preparation is a polypeptide of the invention.

15 Assays for Compounds that Bind RBP

The RBP of the present invention may be used in assays to identify compounds that interact with (e.g., bind to) it.

The compounds which may be screened in accordance with the invention include, but are not limited to peptides, antibodies and fragments thereof, and other
20 organic compounds (e.g., peptidomimetics) that bind to the RBP and either mimic the activity triggered by the natural ligand – rhamnose (i.e., agonists) or inhibit the activity triggered by the natural ligand – rhamnose (i.e., antagonists).

Other compounds that may be screened according to the present invention are peptides, antibodies or fragments thereof, and other organic compounds that
25 mimic the extra cellular domain of the RBP (or a portion thereof) and bind to and "neutralize" natural ligand such as rhamnose.

- Such compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries, antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab').sub.2 and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.
- 10 Computer modelling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate RBP expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites, such as the interaction domains of rhamnose with
- 15 RBP itself. The active site can be identified using methods known in the art including, for example, from study of complexes of RBP with rhamnose. In this regard, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found. Next, the three dimensional geometric structure of the active site is determined. This can be
- 20 done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances.

Having determined the structure of the active site, either experimentally, by modelling, or by a combination, candidate modulating compounds can be

25 identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential RBP modulating

30 compounds.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modelling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

- 10 Further experimental and computer modelling methods useful to identify modulating compounds based upon identification of the active sites of rhamnose and RBP will be apparent to those of skill in the art.

Although described above with reference to design and generation of compounds that could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds that are inhibitors or activators.

Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the RBP and for treating cancer.

- 20 The compounds capable of binding RBP may also be used to identify and isolate RBP homologues. In this regard, the compounds may be used to screen various cell types such as cancer cell types to locate variants of the RBP that could be used to design specific therapeutic agents for treatment of related cancers.

25 In vitro systems may be designed to identify compounds capable of interacting with (e.g., binding to) RBP (including, but not limited to, the extra cellular domain of RBP). These compounds may be useful, for example, in modulating the activity of wild type and/or mutant RBP; elaborating the biological function of the RBP; screening for compounds that disrupt normal RBP interactions; or may in themselves disrupt such interactions.

The principle of the assays used to identify compounds that bind to the RBP involves preparing a reaction mixture of the RBP and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. The RBP species used can vary depending upon the goal of the screening assay. For example, where agonists of the natural ligand are sought, the full length RBP, or a soluble truncated RBP, e.g., in which the transmembrane or cellular domain is deleted from the molecule, a peptide corresponding to the extracellular domain or a fusion protein comprising the RBP extracellular domain fused to a protein or polypeptide that affords advantages in the assay system (e.g., labelling, isolation of the resulting complex, etc.) can be utilized.

The screening assays can be conducted in a variety of ways. For example, one method to conduct such an assay involves anchoring the RBP or fusion protein or the test substance onto a solid phase and detecting RBP/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the RBP may be anchored onto a solid surface, and the test compound, which is not anchored, may be labelled, either directly or indirectly.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the RBP or test compound and drying. Alternatively, an immobilized antibody, such as a monoclonal antibody, specific for the protein to be immobilized may be used to anchor the protein to the solid surface.

In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized

component is pre-labelled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labelled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labelled antibody specific for the previously
5 nonimmobilized component (the antibody, in turn, may be directly labelled or indirectly labelled with a labelled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for RBP or the test compound to anchor any
10 complexes formed in solution, and a labelled antibody specific for the other component of the possible complex to detect anchored complexes.

Cell-based assays can also be used to identify compounds that interact with RBP. To this end, cell lines that naturally express RBP such as a cancer cell line selected from the group comprising: HT-29, LS174-T, AGS, 5637, A431, 786-O,
15 Hs578Bst, CCD 18Lu, HeLa 229, HepG2, JAM, NO36, U87-MG, DV145, LNCaP and A2058, or cell lines (e.g., COS cells, CHO cells, fibroblasts, etc.) that have been genetically engineered to express RBP (e.g., by transfection or transduction of RBP DNA) can be used. Interaction of the test compound with, for example, the extracellular domain of RBP expressed by the host cell can be determined by
20 comparison or competition with native rhamnose.

Diagnostics

The RBP of the present invention and agonists thereof can be employed for the diagnostic and prognostic evaluation of cancer. Such methods may, for example, utilize reagents such as the antibodies described herein. Specifically, such
25 reagents may be used, for example, to detect an over-abundance of RBP relative to normal cells.

Thus, the present invention provides a method for detecting cancer in a sample comprising the steps of: (i) detecting the level of RBP in the sample; and (ii) comparing it to the level of RBP in a sample from a non-cancer source.

The detection method of the present invention may be used to diagnose cancer in vitro. Thus, the present invention provides a method of diagnosing cancer in a patient comprising the steps of: (i) detecting the level of RBP in a sample from the patient; and (ii) comparing it to the level of RBP in a sample from a non-cancer source.

Alternatively, the detection method may be used to diagnose cancer in vivo. In this regard, agents that are adapted to bind to RBP can be labelled and administered to a subject suspected of having cancer and later detected to perform the diagnosis. Thus, the present invention also provides a method of diagnosing cancer in a patient comprising the steps of: (i) detecting the level and/or distribution of RBP in the patient; and (ii) analysing the distribution and/or levels of RBP to identify differences that are indicative of cancer.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific RBP antibody reagent described herein, which may be conveniently used, e.g., in clinical settings, to diagnose patients suspected of having cancer.

RBP antibodies and other agonists of RBP may be used as cancer diagnostics and prognostics, as described herein. Such diagnostic methods may be used to detect abnormalities in the level of RBP and may be performed in vivo or in vitro, such as, for example, on biopsy tissue.

For example, antibodies directed to epitopes of the RBP can be used in vivo to detect the pattern and level of expression of the RBP in the body. Such antibodies can be labelled, e.g., with a radio-opaque or other appropriate compound and injected into a subject in order to visualize binding to the RBP expressed in the body using methods such as X-rays, CAT-scans, or MRI. Labelled antibody fragments, e.g., the Fab or single chain antibody comprising the smallest portion of the antigen binding region may also be used for this purpose. When interpreting the patterns produced according to the diagnostic method, account must be taken on background signal or "noise" from non-cancer cells that also bear the RBP, albeit at lower levels. However, those skilled in the art are

readily able to discern noise from actual signal in performing the diagnosis. Immunoassays or fusion protein detection assays can also be used to diagnose or type cancer in biopsy or autopsy samples in vitro.

Agonists described herein including antibodies, or fragments of antibodies may
5 also be used to quantitatively or qualitatively detect the presence of RBP or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labelled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

The agonists such as antibodies (or fragments thereof) of the present invention
10 may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immuno assays, for in situ detection of RBP or conserved variants or peptide fragments thereof.

In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labelled antibody or fusion protein of the present
15 invention. The antibody (or fragment) or fusion protein is preferably applied by overlaying the labelled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the RBP, or conserved variants or peptide fragments, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will
20 readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

Immunoassays and non-immunoassays for RBP or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been
25 incubated in cell culture, in the presence of a detectably labelled antibody capable of identifying RBP or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support that is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably
5 labelled RBP antibody or other agonist. The solid phase support may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on solid support may then be detected by conventional means.

By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass,
10 polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen
15 or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the
20 same by use of routine experimentation.

With respect to antibodies, one of the ways in which the antibody can be detectably labelled is by linking the same to an enzyme. This then renders the antibody suitable for use in an enzyme immunoassay (EIA). The enzyme that is bound to the antibody will react with an appropriate substrate, preferably a
25 chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alphasglycerophosphate,
30 dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and

acetylcholinesterase. The detection can be accomplished by calorimetric methods that employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

- 5 Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labelling the antibodies, antibody fragments or other agonists, it is possible to detect RBP through the use of a radioimmunoassay (RIA). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by
10 autoradiography.

- It is also possible to label the antibody or other agonist with a fluorescent compound. When the fluorescently labelled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labelling compounds are fluorescein
15 isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

- Agonists such as antibodies can also be detectably labelled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups such as
20 diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

- The antibody or other agonist can also be detectably labelled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that
25 arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labelling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody or other agonist of the present invention. Bioluminescence is a type of

chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labelling are luciferin,
5 luciferase and aequorin.

Methods of Treatment

The ability of the agonists of the present invention bind to RBP and subsequently become internalised in the target cell renders them useful for preferentially delivering agents to cells with a higher load of RBP, such as cancer cells.

- 10 For therapeutic purposes, the agents linked to the agonists of the present invention may be any agent that is adapted to prevent cell growth or division or cause cell death such as, Doxorubicin, Daunorubicin, Vincristine, Vinblastine, Vindesine, Methothrexate, Cytarabine, Etoposide, Cisplatin, Carboplatin, 5-Fluorouracil, Bleomycin, Epirubicin, Cyproterone, Irinotecan etc. When linked to
15 such agents the agonists of the present invention may be used to treat cancer in a patient.

Thus, the present invention provides a method of treating cancer in a subject comprising administering a therapeutically effective amount of a RBP agonist anticancer conjugate to said subject.

- 20 The agonists of the present invention may also be used to treat BEC® overdose. In this regard, if BEC® has been administered to a patient at too high a dose, then an agonist of the present invention may be administered to bind to the RBP of the present invention and prevent or at least reduce BEC® binding.

- 25 Thus, the present invention also comprises a method of treating BEC® overdose in a subject, the method comprising administering an effective amount of an RBP agonist to the subject. Agonists for use in this aspect of the invention may be varied and include RBP antibodies, rhamnose or some other RBP ligand.

Compositions/Administration

This invention also contemplates pharmaceutical or veterinary compositions comprising an agonist of the present invention and a pharmaceutically acceptable carrier. Preferably, the compositions will further comprise an agent adapted to
5 cause cell death such as a glycoside. Pharmaceutical compositions of
proteineous drugs of this invention are particularly useful for parenteral
administration, i.e., subcutaneously, intramuscularly or intravenously. The
compositions for parenteral administration may comprise a solution of the
10 compounds of the invention or a cocktail thereof dissolved in an acceptable
carrier, preferably an aqueous carrier, an emulsion or formulated as micelles in an
appropriate carrier. A variety of aqueous carriers may be employed, e.g., water,
buffered water, 0.4% saline, 0.3% glycine, and the like. These solutions are
preferably sterile and generally free of particulate matter. These solutions may be
15 sterilized by conventional, well known sterilization techniques. The compositions
may further contain pharmaceutically acceptable auxiliary substances as required
to approximate physiological conditions such as pH adjusting and buffering
agents.

The concentration of the compounds of the invention in such pharmaceutical
formulation can vary widely, i.e., from less than about 0.1%, usually at or at least
20 about 1% to as much as 15 or 20% by weight and will be selected primarily based
on fluid volumes, viscosities, etc., according to the particular mode of
administration selected.

Thus, a pharmaceutical composition of the invention for intramuscular injection
could be prepared to contain 1 mL sterile buffered water, and 50 mg of a
25 compound of the invention. Similarly, a pharmaceutical composition of the
invention for intravenous infusion could be made up to contain 250 ml of sterile
Ringer's solution, and 150 mg of a compound of the invention. Actual methods for
preparing parenterally administrable compositions are well known or will be
apparent to those skilled in the art and are described in more detail in, for
30 example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing
Company, Easton, Pa.

The compounds described herein can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional proteins and art-known lyophilization and reconstitution techniques can be employed.

- 5 In situations where the agonist is non-proteineous, it may be administered alone or in combination with pharmaceutically acceptable carriers. The proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets or capsules
- 10 containing such excipients as starch, milk sugar, certain types of clay and so forth. They may be administered sublingually in the form of troches or lozenges in which the active ingredient is mixed with fillers and binders, flavouring agents and dyes; and then dehydrated sufficiently to make it suitable for pressing into a solid form. They may be administered orally in the form of solutions that may be
- 15 injected parenterally, that is, intramuscularly, intravenously or subcutaneously. For parenteral administration, they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.

- The physician or veterinarian will determine the dosage of the present therapeutic
- 20 agents that will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the particular subject under treatment. The physician will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the
- 25 circumstances is reached. It will generally be found that when the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. The compounds are useful in the same manner as other serotonergic agents and the dosage level is of the same order of magnitude as is generally employed with
- 30 these other therapeutic agents. The therapeutic dosage will generally be from 1 to 1000 milligrams per day and higher although it may be administered in several

different dosage units. Tablets containing from 5 to 100 mg. of active agent are particularly useful.

Topical administration

The pharmaceutical compositions of the present invention may be adapted for
5 topical application to a patient.

Various topical delivery systems may be appropriate for administering the compositions of the present invention depending upon the preferred treatment regimen. Topical formulations may be produced by dissolving or combining the agonist of the present invention in an aqueous or nonaqueous carrier. In general,
10 any liquid, cream, or gel, or similar substance that does not appreciably react with the agonist or any other of the active ingredients that may be introduced into the composition and which are non-irritating are suitable. Appropriate non-sprayable viscous, semi-solid or solid forms can also be employed that include a carrier compatible with topical application and have a dynamic viscosity preferably
15 greater than water.

Suitable formulations are well known to those skilled in the art and include, but are not limited to, solutions, suspensions, emulsions, creams, gels, ointments, powders, liniments, salves, aerosols, transdermal patches, etc, which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers,
20 emulsifiers, wetting agents, fragrances, colouring agents, odour controllers, thickeners such as natural gums etc. Particularly preferred topical formulations include ointments, creams or gels.

Ointments generally are prepared using either (1) an oleaginous base, i.e., one consisting of fixed oils or hydrocarbons, such as white petroleum or mineral oil, or
25 (2) an absorbent base, i.e., one consisting of an anhydrous substance or substances which can absorb water, for example anhydrous lanolin. Customarily, following formation of the base, whether oleaginous or absorbent, the active ingredient is added to an amount affording the desired concentration.

Creams are oil/water emulsions. They consist of an oil phase (internal phase),
30 comprising typically fixed oils, hydrocarbons and the like, waxes, petroleum,

mineral oil and the like and an aqueous phase (continuous phase), comprising water and any water-soluble substances, such as added salts. The two phases are stabilised by use of an emulsifying agent, for example, a surface active agent, such as sodium lauryl sulfite; hydrophilic colloids, such as acacia colloidal clays, 5 veegum and the like. Upon formation of the emulsion, the agonist is customarily added in an amount to achieve the desired concentration.

Gels comprise a base selected from an oleaginous base, water, or an emulsion-suspension base. To the base is added a gelling agent that forms a matrix in the base, increasing its viscosity. Examples of gelling agents are hydroxypropyl 10 cellulose, acrylic acid polymers and the like. Customarily, the agonist is added to the formulation at the desired concentration at a point preceding addition of the gelling agent.

The amount of compound incorporated into a topical formulation is not critical; the concentration should be within a range sufficient to permit ready application of the 15 formulation to the affected tissue area in an amount that will deliver the desired amount of agonist to the desired treatment site.

The customary amount of a topical formulation to be applied to an affected tissue will depend upon an affected tissue size and concentration of the agonist in the formulation.

20 In therapeutic applications, compositions of the invention are administered to a subject afflicted with cancer in an amount sufficient to at least improve the condition of the patient and preferably cure the patient of cancer.

Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician or veterinarian. 25 In any event, the composition of the invention should provide a quantity of the compounds of the invention sufficient to effectively treat the cancer in the subject.

Antibodies

Antibodies that specifically recognize one or more epitopes of RBP, or epitopes of conserved variants of RBP, or peptide fragments of the RBP are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric
5 antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

The antibodies of the invention may be used, for example, in the detection of the RBP in a biological sample and may, therefore, be utilized as part of a diagnostic
10 or prognostic technique whereby patients may be tested for abnormal amounts of RBP. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, as described herein for evaluating the effect of test compounds on the ability of RBP to bind its ligand. Additionally, such antibodies may be used to inhibit RBP activity that may be useful in various
15 studies on the dynamics of the binding between the RBP and its ligand.

For the production of antibodies, host animals may be immunized by injection with the RBP or an immunogenic portion thereof such as one corresponding to a functional domain of the RBP, e.g. the extracellular domain. Host animals may include but are not limited to rabbits, mice, and rats, to name but a few.

20 Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminium hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful
25 human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These
30 include, but are not limited to, the hybridoma technique of Kohler and Milstein,

(1975, Nature 256:495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the monoclonals of this invention may be cultivated in vitro or in vivo. Production of high titres of monoclonals in vivo makes this the presently preferred method of production.

10 In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological
15 activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988,
20 Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against the RBP. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments that recognize specific epitopes may be generated by known
25 techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and
30 easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to the RBP can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" the RBP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5): 437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example, antibodies that bind to the
5 RBP and competitively inhibit the binding of rhamnose to the RBP can be used to generate anti-idiotypes that "mimic" the extracellular domain of the RBP and therefore bind rhamnose.

The present invention will now be described with reference to a number of examples. The examples are in no way limiting on the preceding description.

10 Examples

Example 1: Isolation of a rhamnose binding protein using affinity chromatography

Materials/Methods

1. Labelling of rhamnose probes

Biotin Rhamnose-ITC (BRITC) was formed by dissolving Rhamnose-ITC (Sigma
15 R6881; RMM 297.3) in DMSO, diluting it to 1mg/ml in 10mM sodium bicarbonate, pH 9.1 and then adding biotin hydrazide (Sigma, RMM 258.3) at 1:1 or 5:1 molar ratio and allowing the reaction to proceed at room temperature for 16h.

2. Preparation of rhamnose affinity column

Streptavidin sepharose conjugated columns (Amersham 17-5112-01) or free resin
20 (17-5113-01) with a theoretical capacity for biotin labelled rhamnose (BRITC) of 60µg/ml was used. An excess amount of BRITC was dissolved in phosphate buffered saline (PBS) and circulated over the pre-equilibrated column at a flow rate of 0.2ml/min for 30min. Successful coupling of the BRITC was monitored by HPLC analysis of the BRITC-PBS solution.

25 3. Cell lysis

Packed, washed cells were lysed by freeze thawing (-80°C / 4 °C) followed by brief sonication (30-40 sec at 50% duty pulse using 375W sonicator fitted with microtip probe). Cells were lysed in the presence of protease inhibitor cocktail (Roche 1-836-170) in order to minimise proteolysis.

5 4. Multiple Surfactant Solution (MSS)

MSS comprises 5 M urea, 2 M thiourea, 0.002 M n-tributyl phosphine, 0.5% pH 3-10 Pharmalyte carrier ampholytes (Pharmacia, Uppsala) [only in 2-D preparations], 2% 3-([3-cholamidopropyl]-dimethylammonio)-1-propanesulfonate (CHAPS), 2% caprylyl sulfo-betaine, and 0.001% Orange G dye. Material was
10 also treated with endonuclease EC 3.1.30.2 in order to eliminate contaminating DNA.

5. One-dimensional polyacrylamide gel electrophoresis (1D-PAGE)

Pre-cast Tris-HCl 4-20% polyacrylamide gradient gels (Bio-Rad) were used with electrode buffer Tris/glycine, pH 8.3. Sample loading solution: Tris pH 6.8, 0.1%
15 SDS, glycerol, dithiothreitol, bromophenol blue marker.

Electrophoresis conditions: 100V for 90min.

6. Protein visualisation in-gel

This was accomplished either by staining with silver, or with Coomassie R250 in water/ methanol/acetic acid. Fluorescence was visualised using a Fluoro-imager
20 (Pharmacia).

7. Affinity chromatography

Whole cell lysis preparations were prepared using MSS on $10^8 - 10^9$ A2058 cells. The solubilised protein was then diluted 1/50 into HEPES buffered saline containing 140mM NaCl, 2mM $MgCl_2$, and 2mM $CaCl_2$, pH 7.4 (HBS^{2+}) and
25 passed sequentially over a control column (no rhamnose) and the rhamnose affinity column. Each column was washed with HBS^{2+} and eluted with 100mM

rhamnose. Fractions were analysed using acrylamide mini-gels and 1D SDS-PAGE, followed by silver staining.

Results

- 5 A band with a molecular weight of approximately 65kD was visualised in the eluent fractions (Figure 1). No bands were visible in eluent from a corresponding control column that did not contain BRITC (results not shown).

Example 2: Cross-linking the rhamnose binding protein and its ligand

Materials/Methods

(a) Labelling of rhamnose probes

- 10 Fluorescein Rhamnose-ITC (FRITC) was formed by reacting Rhamnose-ITC with fluorescein amine (Sigma F1148, RMM 347.3) at a molar ratio of 1:10 in 10mM sodium bicarbonate pH 9.1.

(b) Cell lysis

As per example 1.

- 15 (c) Multiple Surfactant Solution (MSS)

As per example 1.

(d) One-dimensional polyacrylamide gel electrophoresis (1D-PAGE)

As per example 1.

(e) Protein visualisation in-gel

- 20 As per example 1.

(f) Cell probing

A2058 cells were coated at low density in a microscope compatible chamber. The cells were washed with HBS²⁺ then incubated with FRITC (top concentration of DMSO = 2.5%) for 5-15min at 37°C. The FRITC was removed, the cells
5 washed twice with HBS²⁺ and examined under a visible light microscope. The incubation was repeated with 0-100µM fluorescein-amine, and for 25 and 6µM FRITC using a 10³x excess of unlabelled rhamnose.

(g) Cell Surface Receptor Cross-Linking

A2058 cells prepared in 40ml culture flasks were incubated with FRITC (5 or
10 10µM) as described above and washed once with HBS²⁺. Carbonyl di-imidazole (Aldrich 115533) was dissolved at 1M in DMSO immediately prior to use. This stock solution was then diluted in HBS²⁺ or DMSO to 100µM-10mM and added to the cells at room temperature. After 15min the cross-linker was removed and the flasks stored on ice. Cells were then removed from the flasks by scraping and
15 taken up into MSS lysis buffer. Protein fractions were subjected to SDS-PAGE and the gels visualised as set out above.

(h) Two Dimensional Electrophoresis

Cross linked cells prepared according to method 7 above, using 5µM FRITC, were lysed into 350µl of MSS by cell scraping. This material was prepared for
20 iso-electric focusing by loading onto an 18cm Immobiline DryStrip, pH 3-10 [Amersham], the strip equilibrated and electrophoresed for approx. 150kVhr (Voltage gradient: 200V, 12hr; 250V, 1.5hr; 500V, 2hr; 1000V, 2.5hr; 8000V, 19hr).

The strip was then run in the second dimension using 1-D PAGE according to
25 method 4 above, except a 10% polyacrylamide gel was used. The gel was analysed using a fluorimager and silver stained.

Results

The electrophoretic profile of the protein components from the cross linking experiments are set out in Figure 2A and 2B. Figure 2A depicts the proteins cross-linked to fluorescein that were visualised by fluorescence scanning and Figure 2B depicts the total protein stained with Coomassie brilliant blue.

- 5 The total protein stain indicates that there are approximately equal amounts of protein loaded in each lane. Following FRITC incubation two fluorescently labelled proteins are detectable that are not present in the CDI only lanes. Calibration of the gel using the molecular mass markers (Figure 3) gives masses of 22kD and 68kD for these proteins. However, these masses include one or
10 more FRITC molecules and consequently the mass of the receptor is approximately 67kD.

The results from the two dimensional electrophoresis suggest the fluorescein tagged protein is running with a pI of approximately 6 - 7, and the molecular mass is consistent with prior results.

- 15 Example 3: Staining of cells with a fluorescein tagged rhamnose probe (FRITC)

Materials/Methods

A fluorescein tagged rhamnose probe (FRITC) was prepared as previously described and used to stain A2058 cells.

- FRITC at concentrations from 3-25 μ M was incubated with A2058 cells for 15
20 minutes at 37°C.

Results

- The cells following incubation were found to fluoresce confirming the presence of a rhamnose binding protein on the cells. An image of the cells is depicted in Figure 4 and closer inspection of the stained cells indicates an increased
25 concentration of staining in the cell nucleus, suggesting the rhamnose probe is also taken inside the nuclear membrane. It was found that the staining could be

inhibited by co-incubation of the FRITC and cells with free rhamnose at 10mM concentration.

Example 4 - Effect of Cell Density on Measured LD₅₀ Values

Materials/Methods

- 5 Given that the evaluation of the cytotoxicities for different cell lines needed to be conducted using different sized cell populations, it was considered prudent to determine the effect, if any, of cell number on the measured value of LD₅₀. Five cell lines, HT-29, LS174-T, 5637, A431 and MCF-7 were evaluated at four different seeding cell densities. Hs578T and CCD 18Lu were evaluated at three
10 seeding densities and Hs578Bst, both early and late passage cells, were evaluated at two seeding densities.

- In order that the full range of cell densities be evaluated with at least one cell line, a 3-day version of the cytotoxicity was developed. The cell lines involved were recalibrated for the 3-day format. Multiwell plates were seeded on day 1. Cells
15 were treated with BEC® on day 2 and MTT was added twenty four hours later.

Results

- Plotting the relationship between dose per cell at LD₅₀ and the Day 1 cell density for each cell line, Figure 5, reveals that the behaviours of the epidermoid adenocarcinoma A431, the colorectal adenocarcinoma HT-29 and the normal
20 infant lung fibroblast line, CCD 18Lu, are identical. Similarly, the plots for the colon adenocarcinoma LS174-T and the bladder carcinoma 5637 are almost coincident.

In fact, data from CCD 18Lu, A431, HT-29, LS174T and 5637 can be combined and fitted to a single exponential function,

- 25 ***Dose per seeded cell at LD₅₀ = Intercept x e^{-k x Seeding density} + Limit***

as shown in Figure 6.

This implies that, for these five cell lines the processes of BEC® uptake, including receptor affinity, hydrolytic processing to produce the lysogenic ligand complex, as well as the pathway to cell death, are quantitatively identical.

Similarly, data from the two breast cancer lines, Hs578T, an infiltrating ductal carcinoma and MCF-7, a metastasis from a breast adenocarcinoma, appear to
5 behave similarly to each other but differently from the other lines. These combined data sets can also be fitted to an exponential function, see Figure 7.

Comparing the two fitted functions, two distinct regions are discernable (Figure 8). The functions are virtually coincident at cell densities of 1,500 cells per well and
10 below, conditions under which receptor affinity can be expected to be the major determinant of cytotoxicity (region 1 of figure 8). This suggests that only a single type of receptor is involved in virtually all cell lines included in this study. We estimate that the dissociation constant for this receptor is likely to be of the order of 1.5×10^{-6} M.

15 However, the functions diverge at cell densities greater than 1,500 cells per well (region 2 of figure 8). The difference between the limit values, representing the minimum dose per cell to kill 50% of the susceptible population, is obvious. For LS174-T and 5637 the fitted value of this minimum dose is 300 pg BEC®/cell (71 pg solamargine/cell) while for the breast cancer lines this minimum dose is some
20 three-fold higher at 580 pg BEC®/cell (137 pg solamargine/cell). Such a difference could arise from either a significantly lower number of receptors per cell or slower intracellular processing to produce the isolated ligand complex.

Note from Figure 5 that the behaviour of early passage normal breast fibroblasts differs from late passage cells of the same line. Within the limitations of the
25 restricted data sets these non-tumour cells appear to become more vulnerable to BEC® as they approach senescence.

Example 5 - Single Point Data for Other Cell Lines

Materials/methods

A range of other cell lines were assessed in a similar manner to the assessments carried out in Example 4.

Results

- 5 Figure 10 shows that the single data points for the other cell lines evaluated are plotted, with the exception of MIA PaCa-2, the breast cancer lines and the early passage normal breast fibroblasts, all fall on the same exponential curve of Figure 6.

Example 6 – Co-administration of BEC® and Rhamnose

10 Materials/methods

A2058 cells at two different cell densities were treated with BEC® +/- rhamnose and cell survival was monitored after 4 days. The treatments comprised: (i) BEC® only for 4 days (ii) BEC® only for 5 minutes (iii) BEC® and 5mM rhamnose for 4 days and (iv) BEC® and 5 mM rhamnose for 5 minutes.

15 Results

- Figures 11 and 12 indicate that rhamnose competition with BEC® uptake is more readily observed at the higher cell density (5000 cells). Under these conditions, where the amount of BEC® available to each cell is a major factor determining LD₅₀, the presence of rhamnose at the relatively high concentration of 5 mM
- 20 affects the amount of BEC® taken up by the cells in both 5 minutes and 4 days from solutions in specific concentration ranges. Data in Figure 12 suggests that the rhamnose protective effect is more significant in the pulsed treatment experiment.

Example 7 – Isolation of RBP

25 Materials/Methods

1. Preparation of FRITC

The following reaction mixture was used:

Rhamnose Isothiocyanate [Sigma R6881]	5mg/ml in 500µl DMSO
Fluorescein [Sigma F1148]	50mg in 500µl
100mM sodium hydrogen carbonate	120µl
MilliQ water	80µl

Incubate overnight at room temperature and store at -20°C . Purify FRITC by RP-

5 HPLC:

Column: C18 reverse phase

Solvent A: water + 0.06% tri-fluoro acetic acid (TFA)

Solvent B: 80% acetonitrile (ACN)/ water + 0.06% TFA

10 Analytical gradient 98-50% (A) over 15min. Flow 1ml/min. Wavelength
255nm or 220nm.

Preparative gradient 98% (A) for 2.5min., 98-50% (A) over 20min. Flow
2ml/min. Wavelength 255nm or 220nm.

2. Cell Surface Receptor Cross-Linking

15 A2058 cells were grown to 80-90% confluency in 25ml culture flasks and then
washed with 2x HEPES buffered saline containing 140mM NaCl, 2mM MgCl_2 , and
2mM CaCl_2 , pH 7.4 (HBS^{2+}). FRITC was dissolved in a minimal volume of DMSO
(5-10µl) and added to 1ml HBS^{2+} to give a concentration of 2-10µM FRITC. The
FRITC solution was added to the cells and the flask incubated for 15min at 37°C .
The FRITC was removed, the cells washed once with HBS^{2+} , and freshly
20 prepared carbonyl di-imidazole (100µM in 1ml DMSO) was added immediately at
room temperature. After a minimum of 15min the cross-linker was removed and
the flasks stored on ice.

3. Protein extraction following Receptor Cross-linking

All the DMSO is aspirated from the cells and 300-400µl of MSS (section 10) is added to the flask. The MSS is spread over the entire surface area of the flask and the cells then scraped using a cell scraper/harvester. The cells in MSS are allowed to incubate for 15min at room temperature to remove as much of the protein as possible.

Cell extracts are removed from the flask and added to a fresh tube. The protein is precipitated by adding 1ml of methanol (or acetone) and storing the sample overnight at -80°C. To remove viscous material (e.g. DNA, lipid etc.) the tube was centrifuged for 30min at 13000rpm and 4°C. The methanol was removed and the sample resuspended in 300µl of MSS. To this 1.2 ml of hexane was added and the sample again centrifuged for 30min at 13000rpm and 4°C. The top layer was discarded and any white particulate matter on the surface of the aqueous layer was also removed. Samples were then analysed by SDS-PAGE.

4. Immunoprecipitation of FRITC cross-linked proteins

100µl of protein extract (section 1 above) was diluted to 10ml with 50mM Tris-Cl pH7 and 0.05% Tween 20. In order to pre-clear non-specific binding material 50µl of protein A sepharose [Amersham] was added and incubated overnight at 4°C on a rotating wheel. After incubation, the sample was centrifuged at 2000rpm for 5min to pellet the sepharose. The supernatant was added to 10µl of anti-FITC antibody [Sigma], 50µl of protein A sepharose and incubated overnight at 4°C on a rotating wheel. After incubation the sepharose was washed 2x1ml with 10mM Tris pH 7 and the whole sample (matrix included) was run on 4-20% SDS-PAGE. The gel was then assessed for FRITC labelled proteins by fluorescent detection.

5. 1D PAGE was carried out as in Example 1.

6. Protein visualisation in-gel

To detect fluorescently labelled proteins gels were scanned using a Fluoro-imager (Pharmacia): fluorescein excitation wavelength 494nm, emission wavelength 520nm.

Visual staining was accomplished either with Coomassie G250 in water/methanol/acetic acid or silver staining (PI in-house mass spectrometry compatible protocol; under optimised conditions this is approximately 10-fold less sensitive than previously used methods).

5 Results

1. Preparation of FRITC (Fluorescein Rhamnose Iso-thiocyanate)

Large quantities of fluorescein labelled rhamnose probe (FRITC) were purified by HPLC and their viability confirmed by mass spectrometry. The probe appears
10 stable indefinitely if stored dry at -20°C .

2. Cell Surface Receptor Cross-Linking

Cross linking of FRITC to the surface of A2058 cells was performed successfully
15 in 25ml culture flasks. Large scale FRITC cross-linking (75ml flasks) using identical concentrations of reagent was unsuccessful. This suggests the reaction is readily influenced by micro-changes in the cell environment. Our observations also indicated that an advantageous side effect of using carbonyl di-imidazole cross linker was that the cells became adhered to the flask surface during the
20 procedure and hence were easier to wash.

A cross-linked FRITC protein complex was consistently visible on SDS-PAGE gels by fluorescent imaging (Figure 13).

25 3. Protein extraction following Receptor Cross-linking

Our procedures have focused on maximising the yield of the FRITC-receptor complex, and subsequently isolating the complex from unwanted contaminants. The extraction procedures have involved different protein precipitation methods and subsequent solubilisation steps. The A2058 Receptor-FRITC complex
30 appears fully soluble in multiple surfactant solution (SPRL21111), and partially soluble in a range of non-ionic detergents (2% Tween 20, 2% Triton X-100, 2%

CHAPS), however no single non-ionic detergent has been identified that fully solubilises the complex.

Further, the fluorescent complex appears to be associated with the cell debris/DNA that is precipitated during the initial methanol precipitation. To overcome this problem (of contamination and viscosity) we have developed a two-stage clean-up using methanol, followed by hexane.

4. Immunoprecipitation of FRITC cross-linked proteins

10

The protein-FRITC complex was diluted into a low detergent, low salt buffer and incubated with an antibody directed against fluorescein. Any complexes formed were absorbed onto protein A, precipitated and analysed by SDS-PAGE.

The experiments produced a faint protein band at approx 70kD that was detectable by Coomassie blue staining Figure 14).

15

Further modifications and adaptations not specifically disclosed herein that are apparent to those skilled in the art upon reading this specification are encompassed within the scope of this invention.

References

1. Ashwell, G and Harford, J. (1982) "Carbohydrate specific receptors of the Liver". Ann Rev. Biochem, 51, 531 - 554.
2. Lehrman, MA. *et al* (1986) "The binding of fucose containing glycoproteins by
5 hepatic lectins". J. Biol. Chem., 261 (16) 7412 – 7418.
3. Kolb – Bachofen, V. *et al* (1984) "Gal/NAC/Gal specific rat liver lectins their role in cellular recognition". Biol. Cell, 51, 219 – 226.
4. Cramer, F. and Gabius, HJ. (1991) US Patent 5,225,542.

The Claims Defining the Invention are as Follows

1. An isolated RBP with at least one of the following characteristics:
 - a) a molecular weight of approximately 65-70 kDa and more preferably 66-69kDa;
 - 5 b) a pI of greater than 10 or less than 3;
 - c) a dissociation constant of approximately 1.5×10^{-6} when bound to the rhamnose moiety of solamargine;
 - d) adapted to bind to a rhamnose affinity column prepared according to example 1 and under the conditions set out therein ;
 - 10 e) adapted to be eluted from the column in example 1 with a 100mM rhamnose solution;
 - f) insoluble in aqueous solution; and
 - g) soluble in highly denaturing buffers containing greater than approximately 2% surfactant.
- 15 2. An isolated RBP with at least the following characteristics:
 - a) a molecular weight of approximately 65-70 kDa and more preferably 66-69kDa;
 - b) a dissociation constant of approximately 1.5×10^{-6} when bound to the rhamnose moiety of solamargine;
 - 20 c) adapted to bind to a rhamnose affinity column prepared according to example 1 and under the conditions set out therein ;

- d) adapted to be eluted from the column in example 1 with a 100mM rhamnose solution;
 - e) insoluble in aqueous solution; and
 - f) soluble in highly denaturing buffers containing greater than approximately 2% surfactant.
- 5
3. An isolated RBP according to claim 1 or 2 with a molecular weight of approximately 67kDa.
 4. A method for identifying a compound that binds to an RBP according to any one of the preceding claims comprising the steps of contacting a candidate
10 compound with the RBP and assessing binding.
 5. A method according to claim 4 wherein the compound is an agonist selected from the group comprising peptides, antibodies and fragments thereof, and peptidomimetics.
 6. A method according to claim 4 wherein the compound is an antagonist
15 selected from the group comprising peptides, antibodies and fragments thereof, and peptidomimetics..
 7. A method for identifying a compound that mimics the extra cellular domain of the RBP (or a portion thereof) and binds to rhamnose comprising the steps of contacting a candidate compound with rhamnose and the RBP and assessing
20 whether the compound competes with the RBP for rhamnose.
 8. A method according to any one of claims 4 to 7 wherein the candidate compound is selected from the group comprising: (i) peptides including soluble peptides and members of random peptide libraries or combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino
25 acids; (ii) phosphopeptides including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; (iii) antibodies

(including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies; FAb, F(ab').sub.2 and FAb expression library fragments and epitope-binding fragments thereof); and (iv) small organic or inorganic molecules.


- 5 9. The use of a compound identified using a method according to any one of claims 4-8 for determining a biological function of the RBP or for treating cancer.
10. The use of a compound identified using a method according to any one of claims 4-6 for isolating RBP homologues.
- 10 11. The use of a compound identified using the method of claim 7 for modulating the activity of wild type and/or mutant RBP; elaborating the biological function of the RBP; or screening for compounds that disrupt normal RBP interactions.
12. A method for detecting cancer in a sample comprising the steps of: (i) detecting the level of RBP in the sample; and (ii) comparing it to the level of
15 RBP in a sample from a non-cancer source.
13. A method of diagnosing cancer in a patient comprising the steps of: (i) detecting the level of RBP in a sample from the patient; and (ii) comparing it to the level of RBP in a sample from a non-cancer source.
14. A method of diagnosing cancer in a patient comprising the steps of: (i)
20 detecting the level and/or distribution of RBP in the patient; and (ii) analysing the distribution and/or levels of RBP to identify differences that are indicative of cancer.
15. An immunoassay comprising the step of incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells
25 which have been incubated in cell culture, in the presence of a detectably labelled antibody capable of identifying RBP or conserved variants or peptide fragments thereof, and detecting the bound antibody.

16. The use of an RBP agonist to deliver an agent to a cell with a higher load of RBP, such as cancer cells.
17. An RBP agonist linked to an agent that is adapted to prevent cell growth or division or cause cell death.
- 5 18. An RBP agonist-agent conjugate according to claim 17 wherein the agent is selected from the group comprising Doxorubicin, Daunorubicin, Vincristine, Vinblastine, Vindesine, Methothrexate, Cytarabine, Etoposide, Cisplatin, Carboplatin, 5-Fluorouracil, Bleomycin, Epirubicin, Cyproterone and Irinotecan.
- 10 19. The use of an RBP agonist according to claim 17 or 18 for treating cancer in a patient.
20. The use of an RBP agonist according to claim 17 or 18 for treating BEC® overdose.
21. The use according to claim 19 or 20 wherein the agonist is a RBP antibody,
15 rhamnose or some other RBP ligand.
22. A pharmaceutical or veterinary composition comprising an RBP agonist and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition according to claim 22 further comprising an agent adapted to cause cell death such as a glycoside.
- 20 24. A pharmaceutical composition according to claim 22 or 23 adapted for topical application to a patient.
25. A pharmaceutical composition according to claim 24 in the form of a solution, suspension, emulsion, cream, gel, ointment, powder, liniment, salve, aerosol or transdermal patch.

26. An antibody that specifically recognize one or more epitopes of RBP, or epitopes of conserved variants of RBP, or peptide fragments of the RBP.
27. An antibody according to claim 26 comprising a polyclonal antibody, a monoclonal antibody, a humanized or chimeric antibody, a single chain antibody, Fab fragments, F(ab').sub.2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
28. The use of an antibody according to claim 26 or 27 for detecting RBP in a biological sample.



- 1/13 -

Figure 1




- 2/13 -

Figure 2




- 3/13 -

Figure 3




- 4/13 -

Figure 4




- 5/13 -

Figure 5



- 6/13 -


Figure 6



Parameter	Value	Std. Error
.0124	0.0211	0.0009
1250	0.0013	6.86169e-005
.0015	0.0015	0.0001

- 7/13 -


Figure 7



Parameter	Value	Std. Error
Intercept	0.0315	0.0471
Constant	0.0018	0.0015
Limit	0.0029	0.0002

- 8/13 -

Figure 8




- 9/13 -

Figure 9

Cell line	Type	Cell number	LD50 BEC, ug/mL	Background
AGS	Gastric carcinoma	1250	6.85 +/- 0.10	4.34 +/- 0.89
MIA PaCa-2	Carcinoma, pancreas	2500	11.40 +/- 0.14	7.54 +/- 1.64
786-O	Renal adenocarcinoma cell	625	4.95 +/- 0.04	2.99 +/- 0.32
HeLa 229	Adenocarcinoma, uterine cervix	5000	7.63 +/- 0.09	0.65 +/- 0.83
HepG2	Hepatocellular carcinoma	10000	6.37 +/- 0.19	2.45 +/- 1.65
JAM	Ovarian carcinoma	3750	7.32 +/- 0.16	0.35 +/- 1.65
NO36	Mesothelioma	2500	6.98 +/- 0.11	2.41 +/- 1.20
U87-MG	Glioblastoma, astrocytoma	10000	10.99 +/- 0.38	8.29 +/- 4.01
DV145	Prostate carcinoma	2500	6.78 +/- 0.15	1.83 +/- 1.72
LNCaP	Prostate adenocarcinoma (met)	7500	7.97 +/- 0.18	5.50 +/- 1.91
A2058	Melanoma (met)	5000	7.05 +/- 0.09	0.81 +/- 0.92

- 10/13 -

Figure 10



- 11/13 -

FIGURE 11
A2058, 600 cells






FIGURE 12
A2058, 5000 cells




- 12/13 -

Figure 13



- 13/13 -


Figure 14



INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00135

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ⁷ : C07K 14/705, 16/30, GOIN 33/574, A61K 38/17, 39/395, A61P 35/00												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols)												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, WPIDS, BIOSIS, CAS ON-LINE; Keywords: Rhamnose, Binding Protein, Carbohydrate												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	Grillon C, Monsigny M, Kieda C, "Soluble human lymphocyte sugar binding proteins with immunosuppressive activity", Immunology Letters, (1991 Apr) 28 (1) 47-55 page 48 col. 2 line 28 to page 49 col. 1 line 44, page 51 col. 1 line 29 to col. 2 line 2	1-4										
X	Weebadda W K, Hoover G J, Hunter D B, Hayes M A, "Avian air sac and plasma proteins that bind surface polysaccharides of <i>Escherichia coli</i> 02", Comparative Biochemistry and Physiology, Part B, Biochemistry and Molecular Biology, (2001 Oct) 130 (3) 299-312 page 301 col. 2 lines 25-27, and page 304 lines 16-24.	1-4										
X	Komori Y, Nikai T, Tohkai T, Sugihara H, "Primary structure and biological activity of snake venom lectin (APL) from <i>Agkistrodon p. piscivorus</i> (eastern cottonmouth)", Toxicon (1999 Jul) 37 (7) 1053-64 page 1056 lines 13-16, and page 1057 line 11 to page 1058 line 2.	1-4										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 5 March 2003		Date of mailing of the international search report 18 MAR 2003										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  S.R. IDRUS Telephone No : (02) 6283 2659										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00135

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Amini H R, Ascencio F, Ruiz-Bustos E, Romero M J, Wadstrom T, "Cryptic domains of a 60 kDa heat shock protein of <i>Helicobacter pylori</i> bound to bovine lactoferrin", FEMS Immunology and Medical Microbiology, (1996 Dec 31) 16 (3-4) 247-55 page 249 col. 1 lines 1-6, and page 249 col. 1 line 36 to col. 2 lines 25	1-4
X	Nitta K, Terasaki Y, Kusakari K, Onodera J, Kanno K, Kawauchi H, Takayanagi Y "Comparative studies of carbohydrate-binding proteins from <i>Xenopus laevis</i> skin and eggs. Sugar-binding specificities and affinity purification.", Chemical and Pharmaceutical Bulletin (1990 Apr) 38 (4) 975-81 page 975 col. 2 lines 10-11 and page 977 col. 2 lines 2-3 and Table 1 page 978	1-4
X	Tobin J F, Schleif R F, "Purification and properties of RhaR, the positive regulator of the L-rhamnose operons of <i>Escherichia coli</i> ", Journal of Molecular Biology (1990 Jan 5) 211 (1) 75-89 page 78 col. 2 lines 29-60, and page 86 col. 2 lines 26-28	1-4
X	Tateno H., Saneyoshi A., Ogawa T., Muramoto K., Kamiya H., and Saneyoshi M., "Isolation and Characterization of Rhamnose-binding Lectins from Eggs of Steelhead Trout (<i>Oncorhynchus mykiss</i>) Homologous to Low Density Lipoprotein Receptor Superfamily", Journal of Biological Chemistry, Vol. 273, No. 30 (24 Jul 1998) pp. 19190-19197. page 19194 col. 1 lines 30-40, and page 19193 col. 1 lines 1-3	1-4
X	Daikhora T, Hosono M, Kusakari K, Kawauchi H, Takayanagi Y, Nitta K, "Comparative studies of the agglutination of tumor cells and erythrocytes by <i>Plecoglossus altivelis</i> (Ayu fish) roe lectin", Physico-chemical Biology, (1993) Vol.37 No.1, pp. 31-40 page 32 col. 1 lines 33-39 page 33 col. 1 lines 22-39	1-4 15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00135

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos : 1, 2
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
as no amino acid sequences are given for the RBP claimed, the search conducted did not include a Sequence search.

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all ,
searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite
payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search
report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report
is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.